Arkansas House Bill HB1801

Arkansas 2025 Regular Session

• Introduced: 3/17/25
• Refer: 3/17/25
• Report Pass: 3/20/25
• Engrossed: 3/31/25
• Refer: 3/31/25
• Report Pass: 4/9/25
• Refer: 4/10/25
• Report Pass: 4/15/25
• Enrolled: 4/16/25
• Chaptered: 4/21/25
• Passed: 4/21/25

Caption

To Authorize An Outsourcing Facility Of Legend Drugs And Controlled Substances That Compounds A Product To Sell The Compounded Product To Certain Entities.

Impact

The implementation of HB1801 is intended to streamline the process through which certain healthcare entities can access compounded medications. By officially designating the parameters under which outsourcing facilities can operate, the bill seeks to regulate and ensure the safety and efficacy of compounded drugs. Compliance with federal Good Manufacturing Practices would be mandated, aligning state regulations with those at the federal level, thus fostering an environment of accountability within the state's pharmaceutical landscape.

Summary

House Bill 1801 aims to authorize registered outsourcing facilities of legend drugs and controlled substances to sell compounded products to specific entities within Arkansas. The bill outlines the criteria for these facilities, emphasizing the requirements for registration with the U.S. Food and Drug Administration and obtaining a permit from the Arkansas State Board of Pharmacy. The primary entities that can receive the compounded products include licensed retail pharmacies, healthcare facilities, and licensed healthcare providers. This advancement is proposed to enhance the availability of compounded medications for Arkansas residents.

Contention

Some points of contention may arise regarding the restrictions placed on the sale of compounded products. The bill specifically forbids outsourcing facilities from selling compounded products to wholesalers or any indirect entities, which may raise concerns about accessibility and flexibility for practitioners who sometimes require compounded medications for specialized patient needs. The delineation between what constitutes an outsourcing facility and other types of pharmaceutical entities will need to be carefully managed to avoid legal ambiguities during enforcement.